Becton Dickinson vs Boston Scientific
Becton Dickinson and Boston Scientific are similar in size: $21.84bn and $20.07bn of revenue in their latest fiscal years. Boston Scientific grew faster (19.9% against 8.2%). Boston Scientific kept more of each dollar of sales as profit: a net margin of 14.4% against 7.7%. Boston Scientific carries less debt relative to equity (47.2% against 75.5%).
| Latest fiscal year | Becton DickinsonBDX, 2025 | Boston ScientificBSX, 2025 |
|---|---|---|
| Revenue | $21.84bn | $20.07bn |
| Revenue growth | 8.2% | 19.9% |
| Net income | $1.68bn | $2.90bn |
| Operating margin | 11.8% | 18.0% |
| Net margin | 7.7% | 14.4% |
| Return on equity | 6.5% | 12.6% |
| Free cash flow | $2.67bn | $3.66bn |
| Cash | $567m | $1.97bn |
| Total debt | $19.18bn | $11.44bn |
| Debt to equity | 75.5% | 47.2% |
| Dividend per share | $4.16 | — |
| Dividend yield | 2.1% | — |
| Share buybacks | $1.00bn | — |
| Employees | 72,000 | 59,000 |
| Market value | $54.23bn | $63.03bn |
| Price vs our value range | Within our value range | Within our value range |
| Moat score | 70 (Strong) | 73 (Strong) |
| Insider trades, 12 months | 0 buys, 22 sales | 10 buys, 7 sales |